• Actuate Therapeutics plans to initiate a Phase 1/2 trial of oral elraglusib in first-quarter 2027, initially targeting metastatic melanoma.
• The trial will evaluate elraglusib as a single agent, with potential expansion into other advanced solid tumors.
• Preclinical testing in an aggressive melanoma mouse model showed significant tumor growth inhibition, increased antitumor immune activity and favorable tolerability.
• The findings will be presented November 18, 2026, at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Actuate Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611040800PRIMZONEFULLFEED9869934) on November 04, 2026, and is solely responsible for the information contained therein.